

**PART B - FEE(S) TRANSMITTAL**

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, Virginia 22313-1450**  
**or Fax** (571)-273-2885

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

57263 7590 05/09/2006

**KING & SPALDING LLP**  
**191 PEACHTREE STREET**  
**ATLANTA, GA 30303-1763**

08/15/2006 HUONG2 00000044 10607909

01 FC:1504	300.00 OP
02 FC:1501	1400.00 OP
03 FC:8001	45.00 OP

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

**Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

**John Ezcurra**

(Depositor's name)

*John Ezcurra*

(Signature)

August 9, 2006

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/607,909	06/27/2003	Jean-Pierre Sommadossi	IDX 1031 06171.105088	8101

TITLE OF INVENTION: 2'-C-METHYL-3'-O-L-VALINE  
 INFECTIONS ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$300	\$1700	08/09/2006
EXAMINER	ART UNIT		CLASS-SUBCLASS		
MCINTOSH III, TRAVISS C	1623		514-049000		

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  
 (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Sherry M. Knowles, Esq.

2 \_\_\_\_\_

3 King & Spalding LLP

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

**Idenix Pharmaceuticals, Inc.**  
**Universita Degli Studi Di Cagliari**

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

**Cambridge, MA**

**Cagliari, Italy**

Please check the appropriate assignee category or categories (will not be printed on the patent):  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are enclosed:

- Issue Fee  
 Publication Fee (No small entity discount permitted)  
 Advance Order - # of Copies 15

4b. Payment of Fee(s):

- A check in the amount of the fee(s) is enclosed.  
 Payment by credit card. Form PTO-2038 is attached.  
 The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 11-0980 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature

Typed or printed name Sherry M. Knowles, Esq.

Date August 9, 2006

Registration No. 33,052

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/607,909

Applicants : Sommadossi *et al.*

Filed : June 27, 2003

TC/A.U. : 1623

Title : 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections

Examiner : Traviss C. McIntosh III

Docket No. : 06171.105088 (IDX 1031)

Customer No. : 57263

August 9, 2006

**ISSUE FEE TRANSMITTAL**

---

Sir:

Applicants enclose the PTOL-85B Issue Fee Transmittal Form and payment of the issue fee in the above-referenced application. Applicants believe that the issue fee is \$1400.00 for a large entity, the publication fee is \$300.00 and the advanced order fee for fifteen extra copies of the issued patent is \$45.00 (15 x \$3.00). Enclosed is a check for \$1,745.00. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 11-0980.

As requested in the Notice of Allowability, Applicants confirm the election of Group I, claims 1-7, 13-18, 37-38, 43-44 and 46-67.

Respectfully submitted,

  
\_\_\_\_\_  
Sherry M. Knowles, Esq.  
Registration No. 33,052

KING & SPALDING  
1180 Peachtree Street  
Atlanta, Georgia 30309  
404-572-3541 (Telephone)  
404-572-5134 (Facsimile)



CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Transmittal of Issue Fee, Form PTOL-85, check for \$1745.00 and postcard along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage for first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313.

John Ezcurra  
John Ezcurra

Date: Aug. 9, 2006